# Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

> **NCT05437120** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-121/TEZ/D-IVA

## Key facts

- **NCT ID:** NCT05437120
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-22
- **Primary completion:** 2023-03-16
- **Final completion:** 2023-03-16
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05437120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05437120, "Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05437120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*